MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. GTBIF
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Green Thumb Industries (GTBIF) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Green Thumb Industries
OTC Markets OTCQX•Healthcare•Drug Manufacturers - Specialty & Generic
$7.25-0.24(-0.03%)Market closed
Market Cap
$1.62B
P/E
12.8x
P/S
1.3x
P/B
0.9x

Green Thumb Industries Inc. manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States. It operates through two segments, Retail and Consumer Packaged Goods. The company offers cannabis flower; processed and packaged products, including pre-rolls, concentrates, vapes, tinctures, edibles, topicals, capsules, tinctures, and other cannabis-related products under the &Shine, Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, RYM, and RHYTHM brands. It distributes its products to third-party licensed retail customers; and sells finished products to third-party licensed retail cannabis stores. Green Thumb Industries Inc. was founded in 2014 and is headquartered in Chicago, Illinois.

B

How this company scores

GoodMetricSide Score: 75/100

Strongest: Cash & Earnings Quality (25/25); weakest: Profitability (14/25).

Profitability14/25
Growth19/25
Balance Sheet & Red Flags17/25
Cash & Earnings Quality25/25
Strengths
Rising free cash flowRising earningsLow leverageCash-backed earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 12.8x5y range 10.7x – 171.1x
P/E 12.8x · below its 17-quarter median

Currently below its 17-quarter median.

P/S · 1.3x5y range 1.1x – 7.5x
P/S 1.3x · below its 20-quarter median

Currently below its 20-quarter median.

P/B · 0.9x5y range 0.7x – 4.3x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 38.3% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Price & Volume
Market Cap $1.62B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$1.21B
7Q
Q. Revenue
$306.68M
5%
TTM EBITDA
$268.44M
10%
TTM Op. Income
$116.49M
6Q
Q. Op. Income
$19.97M
49%
TTM Net Income
$126.77M
4Q
Q. Net Income
$4.88M
2Q
EPS
$0.02
2Q
Shares Out.
$221.02M
2Q
$1.21B in TTM revenue grew 4.8% YoY, reaching $306.68M last quarter. TTM EBITDA of $268.44M and TTM operating income of $116.49M show growth is flowing through to the bottom line. TTM net income of $126.77M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
45.0%
10%
EBITDA Margin
17.3%
26%
Op. Margin
6.5%
52%
Net Margin
1.6%
2Q
Op. margin of 6.5% is down 6.9% YoY — costs are rising relative to revenue. Net margin at 1.6% and gross margin of 45.0% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 52% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
12.8x
71%
P/S Ratio
1.3x
19%
P/B Ratio
0.9x
21%
At 12.8x P/E, the stock trades below typical market levels. P/S of 1.3x and P/B of 0.9x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 71% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$2.82B
10%
Cash
N/A
2Q
Long-Term Debt
$259.28M
11%
Book Value
$1.86B
2Q
D/E Ratio
0.1
7%
Debt/EBITDA
4.9
2Q
With $2.82B in assets and $259.28M in long-term debt, D/E is 0.1and book value is $1.86B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is up 7% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$29.01M
2Q
TTM Free Cash Flow
$197.77M
55%
FCF Margin
16.4%
48%
FCF / Net Income
1.6
4Q
TTM FCF of $197.77M on $29.01M in operating cash flow. The FCF / Net Income ratio of 1.6x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 55% — a weakening trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
P/B 0.9x
· below its 20-quarter median

Currently below its 20-quarter median.